ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2026
Rapid Decentralized Prostate Cancer Risk Stratification by Portable Liquid Biopsy Analysis within a Clinical Biosensor Validation Framework.
Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
Abstract
Clinical liquid biopsy (e.g., blood or urine) specimens, as a minimally invasive source of crucial molecular information, continue to grow in importance for efficacious targeted cancer treatment. Yet, current molecular profiling technologies are still confined to centralized laboratory testing, which escalates testing costs, result turnaround time, and patient anxiety. Crucially, there is also a scarcity of purposeful clinical validation studies to rigorously evaluate emerging liquid biopsy technologies from research settings to facilitate clinical translation. Here, we report liquid biopsy biosensor advancements in achieving rapid, accurate, and decentralized molecular profiling of a clinically accredited prostate cancer (PCa) urinary circulating RNA biomarker panel. This biosensor approach, termed 'Accelerated non-inVasive bioAnalyte testing And Reporting' (AVATAR), integrates accelerated isothermal assay chemistry and wireless mobile operation capabilities onto a portable electrochemical readout platform. AVATAR enables easy operational control and result display with a custom mobile app following liquid biopsy specimen collection. Using independent training (n = 124) and validation (n = 114) PCa clinical urinary specimen cohorts, we showed AVATAR achieved superior PCa risk stratification to current clinical PCa testing with area-under-curve values of 0.88 (95% confidence interval: 0.84-0.92) and 0.86 (95% confidence interval: 0.83-0.89), respectively within 55 min of assay time. To further accelerate AVATAR for using PCa liquid biopsies as a surrogate for invasive tissue sampling, we designed a tailored multi-year PCa follow-up study with individual patient liquid biopsy specimens showing strong molecular biomarker correlation with comprehensive transcriptomic sequencing of matched tissue specimens (n = 39). By creating this bespoke biosensor technology clinical translation framework, we demonstrated AVATAR for decentralized PCa liquid biopsy molecular profiling to augment clinical precision cancer management planning.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.